164 related articles for article (PubMed ID: 2904635)
1. Serotonergic component of SCH 23390: in vitro and in vivo binding analyses.
McQuade RD; Ford D; Duffy RA; Chipkin RE; Iorio LC; Barnett A
Life Sci; 1988; 43(23):1861-9. PubMed ID: 2904635
[TBL] [Abstract][Full Text] [Related]
2. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors.
Bischoff S; Heinrich M; Sonntag JM; Krauss J
Eur J Pharmacol; 1986 Oct; 129(3):367-70. PubMed ID: 3536532
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP syndrome.
Bischoff S; Heinrich M; Krauss J; Sills MA; Williams M; Vassout A
J Recept Res; 1988; 8(1-4):107-20. PubMed ID: 3290470
[TBL] [Abstract][Full Text] [Related]
4. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of binding of 3H-SCH-23390 to D-1 dopaminergic receptor sites in rat striatal tissue.
Faedda G; Kula NS; Baldessarini RJ
Biochem Pharmacol; 1989 Feb; 38(3):473-80. PubMed ID: 2563653
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the selectivities of SCH 23390 with BW737C89 for D1, D2 and 5-HT2 binding sites both in vitro and in vivo.
Riddall DR
Eur J Pharmacol; 1992 Jan; 210(3):279-84. PubMed ID: 1351844
[TBL] [Abstract][Full Text] [Related]
7. Striatal D1- and D2-dopamine receptor sites are separately detectable in vivo.
Leslie CA; Bennett JP
Brain Res; 1987 Jul; 415(1):90-7. PubMed ID: 2957025
[TBL] [Abstract][Full Text] [Related]
8. In vivo binding of SCH 39166: a D-1 selective antagonist.
McQuade RD; Duffy RA; Coffin VL; Chipkin RE; Barnett A
J Pharmacol Exp Ther; 1991 Apr; 257(1):42-9. PubMed ID: 1826927
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the radioiodinated analogue of SCH 23390: in vitro and in vivo D-1 dopamine receptor binding studies.
McQuade RD; Chipkin R; Amlaiky N; Caron M; Iorio L; Barnett A
Life Sci; 1988; 43(14):1151-60. PubMed ID: 3050344
[TBL] [Abstract][Full Text] [Related]
10. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
O'Boyle KM; Waddington JL
Eur J Pharmacol; 1984 Mar; 98(3-4):433-6. PubMed ID: 6144559
[TBL] [Abstract][Full Text] [Related]
11. Characterization of [125I]SCH 23982 binding in human brain: comparison with [3H]SCH 23390.
Laruelle M; Sidhu A; Casanova MF; Weinberger DR; Kleinman JE
Neurosci Lett; 1991 Oct; 131(2):273-6. PubMed ID: 1837073
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo binding of (E)- and (Z)-N-(iodoallyl)spiperone to dopamine D2 and serotonin 5-HT2 neuroreceptors.
Lever JR; Scheffel UA; Stathis M; Musachio JL; Wagner HN
Life Sci; 1990; 46(26):1967-76. PubMed ID: 2362552
[TBL] [Abstract][Full Text] [Related]
13. Interaction of flunarizine with dopamine D2 and D1 receptors.
Ambrosio C; Stefanini E
Eur J Pharmacol; 1991 May; 197(2-3):221-3. PubMed ID: 1833208
[TBL] [Abstract][Full Text] [Related]
14. [3H]SCH 39166, a new D1-selective radioligand: in vitro and in vivo binding analyses.
McQuade RD; Duffy RA; Anderson CC; Crosby G; Coffin VL; Chipkin RE; Barnett A
J Neurochem; 1991 Dec; 57(6):2001-10. PubMed ID: 1834801
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.
Billard W; Ruperto V; Crosby G; Iorio LC; Barnett A
Life Sci; 1984 Oct; 35(18):1885-93. PubMed ID: 6387355
[TBL] [Abstract][Full Text] [Related]
16. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
Urwyler S; Markstein R
J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
[TBL] [Abstract][Full Text] [Related]
17. Characterization of binding of 3H-SCH 23390 to dopamine D-1 receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions.
Hyttel J; Arnt J
J Neural Transm; 1987; 68(3-4):171-89. PubMed ID: 2881976
[TBL] [Abstract][Full Text] [Related]
18. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
19. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
Makman MH; Dvorkin B
Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with antidepressants decreases the number of [3H]SCH 23390 binding sites in the rat striatum and limbic system.
Klimek V; Nielsen M
Eur J Pharmacol; 1987 Jul; 139(2):163-9. PubMed ID: 3308491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
